Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries
- PMID: 28789880
- DOI: 10.1016/j.jhep.2017.06.035
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries
Comment in
-
Reply to: "Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries".J Hepatol. 2017 Dec;67(6):1350-1352. doi: 10.1016/j.jhep.2017.07.019. Epub 2017 Aug 5. J Hepatol. 2017. PMID: 28789882 No abstract available.
Comment on
-
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.J Hepatol. 2017 May;66(5):910-918. doi: 10.1016/j.jhep.2017.01.007. Epub 2017 Jan 18. J Hepatol. 2017. PMID: 28108232
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

